Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
PHP Toggle Menu

Category: 2024

Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC)

C. Le Tourneau, et al. SITC 2024  Abstract available on the SITC website – Download the abstract and the poster

Published 7 November 2024
Categorized as 2024, Myvac, Publication, publication key en, TG4050

Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024

SITC 2024

Published 7 November 2024
Categorized as 2024, Myvac, Press release, TG4050

Transgene Reports Business, Pipeline and Financial Update for Q3 2024

Financial Q3 2024

Published 7 November 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release

Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Develpment

ProBioGen

Published 5 November 2024
Categorized as 2024, categorie-orpheline, dates, dates, Myvac, Press release

TG7010: a Novel Chimeric Oncolytic Poxvirus Encoding IL-12 with Improved Properties for Systemic Delivery

J. Foloppe, et al. IOVC 2024  Abstract available on the IOVC website – Download the abstract and the poster

Published 27 October 2024
Categorized as -others, 2024, Invir.IO, Publication

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers

TG4001 2024

Published 14 October 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release, TG4001, TG4001

Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024

SITC 2024

Published 7 October 2024
Categorized as 2024, dates, Myvac, Press release, TG4050

Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025

H1 2024 FINANCIAL RESULTS

Published 24 September 2024
Categorized as 2024, categorie-orpheline, dates, dates, Press release

Oncolytic viruses alter the biogenesis of tumor extracellular vesicles and influence their immunogenicity

U. Hirigoyen, et al. Oncology 2024 Article available on the Molecular Therapy Oncology website – Download the Article

Published 24 September 2024
Categorized as -others, 2024, Invir.IO, Publication

Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors

S. Champiat, et al. ESMO 2024  Abstract available on the ESMO website – Download the abstract and the poster

Published 14 September 2024
Categorized as 2024, BT-001, Publication

Posts pagination

Page 1 … Page 4 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
Menu